ET-1 expression and growth inhibition of prostate cancer cells: a retinoid target with novel specificity

Area of Science:

• Molecular Biology
• Cancer Research
• Endocrinology

Background:

• Endothelin-1 (ET-1) is a vasoconstrictor and a growth stimulator in various cancers, including prostate cancer.
• Blocking ET-1 production may inhibit tumor growth and metastasis.
• Retinoids, including all-trans-retinoic acid, show potential in cancer therapy.

Purpose of the Study:

• To investigate the effect of synthetic retinoids on prostate cancer cell growth.
• To determine the role of endothelin-1 (ET-1) in retinoid-mediated growth inhibition.
• To elucidate the molecular mechanisms underlying cell-specific responses to retinoids in prostate cancer.

Main Methods:

• Treatment of LNCaP and DU145 prostate cancer cells with synthetic retinoids and all-trans-retinoic acid.
• Assessment of cell growth and ET-1 gene expression using reverse transcription-PCR.
• Transfection of ET-1 promoter constructs with wild-type or mutated AP-1 and GATA-2 sites into prostate cancer cells.

Main Results:

• Retinoids repressed LNCaP cell growth and suppressed ET-1 gene expression.
• Androgen-insensitive DU145 cells were resistant to retinoid treatment.
• LNCaP cells require both AP-1 and GATA-2 sites for ET-1 promoter activation, while DU145 cells involve additional factors.
• Anti-AP-1 selective retinoids did not inhibit ET-1 promoter activity or LNCaP cell growth, indicating structural requirements for retinoid efficacy.

Conclusions:

• Synthetic retinoids can inhibit prostate cancer cell growth by downregulating ET-1 expression, particularly in androgen-sensitive LNCaP cells.
• The differential response of LNCaP and DU145 cells to retinoids is linked to distinct mechanisms of ET-1 gene regulation involving AP-1 and GATA-2 transcription factors.
• Specific retinoid structures are necessary for inhibiting ET-1 promoter activity and achieving cell growth inhibition, suggesting targeted therapeutic strategies.